Abstract
Background: MicroRNA-19b (miR-19b) is essential in determining oligodendroglia proliferation. Phosphatase and tensin homologue on chromosome 10 (PTEN) is considered the target of miR-19b and participates in oligodendrocyte differentiation and proliferation.
Methods: Murine EAE was induced by myelin oligodendrocyte glycoprotein (MOG35– 55). For EAE reversal, artificially synthesized agomiR-19b was intravenous injected after immunization.
Results: We found that the expression of miR-19b is significantly reduced in an experimental autoimmune encephalomyelitis (EAE) mouse model. This downregulation, which is associated with the neurological scores, can be dramatically ameliorated by agomiR-19b. Our results show that agomiR-19b increases the expression of myelin basic protein (MBP) and cyclic nucleotide phosphodiesterase (CNP), which are regularly utilized as molecular markers of oligodendrocytes. Furthermore, our study also revealed that miR-19b probably affects the expression of PTEN in the EAE model.
Conclusion: These results indicate that the restoration of miR-19b probably exerts its therapeutic effect by affecting PTEN in the pathogenesis of EAE.
Keywords: MiR-19b, experimental autoimmune encephalomyelitis, oligodendrocyte, PTEN, agomiR-19b, MBP, CNP.
Current Molecular Medicine
Title:MiR-19b Functions as a Potential Protector in Experimental Autoimmune Encephalomyelitis
Volume: 18 Issue: 5
Author(s): B. Hu, Z.L. Hu, Q.M. Zeng, B. Xiao and H. Yang*
Affiliation:
- Department of Neurology, Xiangya Hospital of Central South University, Changsha, 410008,China
Keywords: MiR-19b, experimental autoimmune encephalomyelitis, oligodendrocyte, PTEN, agomiR-19b, MBP, CNP.
Abstract: Background: MicroRNA-19b (miR-19b) is essential in determining oligodendroglia proliferation. Phosphatase and tensin homologue on chromosome 10 (PTEN) is considered the target of miR-19b and participates in oligodendrocyte differentiation and proliferation.
Methods: Murine EAE was induced by myelin oligodendrocyte glycoprotein (MOG35– 55). For EAE reversal, artificially synthesized agomiR-19b was intravenous injected after immunization.
Results: We found that the expression of miR-19b is significantly reduced in an experimental autoimmune encephalomyelitis (EAE) mouse model. This downregulation, which is associated with the neurological scores, can be dramatically ameliorated by agomiR-19b. Our results show that agomiR-19b increases the expression of myelin basic protein (MBP) and cyclic nucleotide phosphodiesterase (CNP), which are regularly utilized as molecular markers of oligodendrocytes. Furthermore, our study also revealed that miR-19b probably affects the expression of PTEN in the EAE model.
Conclusion: These results indicate that the restoration of miR-19b probably exerts its therapeutic effect by affecting PTEN in the pathogenesis of EAE.
Export Options
About this article
Cite this article as:
Hu B. , Hu Z.L., Zeng Q.M., Xiao B. and Yang H. *, MiR-19b Functions as a Potential Protector in Experimental Autoimmune Encephalomyelitis, Current Molecular Medicine 2018; 18 (5) . https://dx.doi.org/10.2174/1566524018666181004123716
DOI https://dx.doi.org/10.2174/1566524018666181004123716 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Genetically-Modified Hematopoietic Stem Cells and their Progeny for Widespread and Efficient Protein Delivery to Diseased Sites: The Case of Lysosomal Storage Disorders
Current Gene Therapy Potential Relevance of Melatonin Against Some Infectious Agents: A Review and Assessment of Recent Research
Current Medicinal Chemistry An Update on Animal Models of Autoimmune Hepatitis: Are we There Yet?
Current Pharmaceutical Design Small Molecule Inhibitors of PKCθ as Potential Antiinflammatory Therapeutics
Current Topics in Medicinal Chemistry Glitazones, PPAR-γ and Neuroprotection
Mini-Reviews in Medicinal Chemistry Subject Index
Current Drug Targets - Inflammation & Allergy Functional Interactions Between B Lymphocytes and the Innate Immune System
Infectious Disorders - Drug Targets Immunosuppressive Properties of Mesenchymal Stem Cells: Advances and Applications
Current Molecular Medicine Regulatory T Cells as Targets for Immunotherapy of Autoimmunity and Inflammation
Inflammation & Allergy - Drug Targets (Discontinued) Induced Stem Cells as a Novel Multiple Sclerosis Therapy
Current Stem Cell Research & Therapy Anti-Arthritic Effects of Immunomodulatory Peptide Injected in Joints
Current Drug Delivery The Prospect of Stem Cells as Multi-Faceted Purveyors of Immune Modulation, Repair and Regeneration in Multiple Sclerosis
Current Stem Cell Research & Therapy Glia: An Important Target for Anti-Inflammatory and Antidepressant Activity
Current Drug Targets Peroxisome Proliferator-Activated Receptors and the Control of Inflammation Update
Medicinal Chemistry Reviews - Online (Discontinued) Possible Pathomechanisms Responsible for Injury to the Central Nervous System in the Settings of Chronic Cerebrospinal Venous Insufficiency
Reviews on Recent Clinical Trials Dysregulation of SIRT-1 Signaling in Multiple Sclerosis and Neuroimmune Disorders: A Systematic Review of SIRTUIN Activators as Potential Immunomodulators and their Influences on other Dysfunctions
Endocrine, Metabolic & Immune Disorders - Drug Targets Erythropoietin and Wnt1 Govern Pathways of mTOR, Apaf-1, and XIAP in Inflammatory Microglia
Current Neurovascular Research Neuropeptides as Therapeutic Approach to Autoimmune Diseases
Current Pharmaceutical Design SIRT1 Promotes Neuronal Fortification in Neurodegenerative Diseases through Attenuation of Pathological Hallmarks and Enhancement of Cellular Lifespan
Current Neuropharmacology CD4+CD25+ Regulatory T-Cell Therapy for Allergy, Autoimmune Disease and Transplant Rejection
Inflammation & Allergy - Drug Targets (Discontinued)